Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune condition causing widespread organ damage and cytopenias secondary to excessive inflammation and hemophagocytosis. The disease may be primary in nature resulting from a genetic cause or may be secondary to another clinical process, such as a rheumatologic, autoimmune, infectious or malignant disorder. Familial hemophagocytic lymphohistiocytosis (FHL) can be sub-divided into FHL-1 through FHL-5, with a yet to be determined genetic mutation causing FHL-1 but PFR-1, UNC13D, STX11 and STXBP2 gene defects causing FHL-2 through FHL-5, respectively. While treatment of secondary HLH primarily involves controlling the triggering condition, allogeneic hematopoietic stem cell transplantation (HSCT) is essential to the survival of FHL patients. 1 Symptoms of HLH may begin in early infancy and in utero on occasion.
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Here we review the cases of two brothers with genetically defined HLH. The first was managed with conventional dose medical therapy followed by allogeneic HSCT to correct the underlying immune disorder. The second case was recognized in utero using prenatal diagnosis and managed in a more novel manner with preemptive protective isolation and allogeneic HSCT prior to the onset of clinical HLH. Both siblings were treated on a prospective, IRB-approved clinical trial of unrelated cord blood HSCT.
The elder sibling, sibling A, was delivered vaginally at term. His perinatal course was unremarkable and hepatitis B immunization at birth and 2 month vaccinations were given without incident. At 3 months of age he presented with fevers and fatigue in association with a human metapneumovirus upper respiratory infection. Examination showed hepatosplenomegaly, lymphadenopathy and maculopapular rash. Laboratory evaluations revealed WBC 3300/µL, hemoglobin 9.3 g/dL and platelets 53000/µL. Bone marrow was normocellular and without evidence of malignancy or hemophagocytosis. Serum ferritin, triglyceride and IL-2 receptor (IL-2R) levels were markedly elevated. A diagnosis of hemophagocytic lymphohistiocytosis was made. Further testing revealed absent natural killer cell function and compound heterozygosity for MUNC13-4 protein mutations (2650 C4T (Q884X) and 2732_2740 delins CTC). Treatment was initiated with dexamethasone, etoposide and cyclosporine. Following initial therapy, the child's condition improved and serum ferritin and IL-2R levels declined. Given the diagnosis of familial HLH, the patient proceeded to allogeneic HSCT at 10 months of age. Reduced intensity HSCT conditioning with Campath, fludarabine and melphalan was used. HSCT was with a single unrelated cord blood unit matched at 7 of 8 HLA-A, B, C and DRB1 alleles and providing cell doses of 12.1x10e7 nucleated cells and 2.45x10e5 CD34/kg. Neutrophil engraftment was achieved at day +13 and platelet engraftment at day +25. Day +100 marrow and peripheral blood at 3 years post HSCT showed full donor chimerism. Post-HSCT complications included staph aureus bacteremia and Grade 3 acute graft versus host disease (GVHD) involving the skin and gut. At 7.5 years post HSCT, sibling A is doing well and off all HSCT-related medications.
At 3 months post transplant of sibling A, the child's mother became pregnant with sibling B. Chorionic villus sampling (CVS) genetic analysis in utero at 3 months gestation showed the same HLH mutations as his sibling. HLA typing was completed on CVS DNA isolates as well. Sibling B was born vaginally at 38.5 weeks gestation and was immediately placed in protective isolation to prevent infectious triggers of HLH. Vaccinations were withheld. Initial CBC was normal for age. On day of life five, serum IL-2R level was elevated, but ferritin and triglyceride levels were normal. Bone marrow analysis at 6 weeks of age revealed no evidence of hemophagocytosis. HLH genetic testing and HLA typing were repeated and confirmed post-delivery. Prior to transplantation, serum IL-2 receptor levels had increased further, but ferritin remained normal. Given sibling B's complete immune competence prior to HSCT, myeloablative, rather than reduced intensity, preparative therapy consisting of busulfan, cyclophosphamide and equine anti-thymocyte globulin was given at 8 weeks of age. Transplant was with a single unrelated cord blood unit matched at 7 of 8 HLA-A, B, C and DRB1 alleles and providing cell doses of 16.6x10e7 nucleated cells and 1.8x10e5 CD34+ cells/kg. Neutrophil engraftment was achieved at day +20 and platelet engraftment occurred at day +25. Post-HSCT complications included Grade 3 acute GVHD involving the skin and liver. There were no infectious complications. Now 6.5 years post transplant, sibling B continues to be disease free with 100% donor chimerism and no evidence of GVHD off all HSCT-related medications.
This report describes several novel strategies for evaluation and management of familial hemophagocytic lymphohistiocytosis. Moreover, to the best of our knowledge, it represents the first published description of preemptive protective isolation and allogeneic HSCT for prenatally diagnosed familial HLH prior to the onset of clinical disease. Having a known diagnosis of FHL secondary to previously defined MUNC13-4 mutations in sibling A allowed genetic analysis and HLA typing via chorionic villus sampling in the gestational period of sibling B. Early diagnosis, especially prenatal, offers many potential benefits to those with an immunologic disorder, such as HLH and SCID. It has been found that in SCID, very early diagnosis can significantly improve outcomes, most notably transplant outcome. 4 It can be assumed that prenatal diagnosis would also likely improve outcomes in FHL by avoiding intercurrent disease-related complications.
Sibling B's in utero diagnosis at 3 months gestation allowed for early HLA typing via CVS. Search for a suitably matched transplant donor, therefore, was initiated well in advance of birth and allowed sufficient time to secure an appropriate stem cell source. Immediately following delivery, sibling B was placed in a protective environment and immunizations were withheld to minimize the risk of triggering clinical HLH activity. Similar protective measures are undertaken in patients with SCID, but isolation of FHL patients from birth is an innovative management approach and was only feasible for our patient given his prenatal diagnosis.
HLH disease status at the time of transplantation has a major impact on survival. Long-term results of the HLH-94 treatment protocol demonstrated 5-year cumulative survival after HSCT of 58% in children with active disease versus 72% in those whose disease had been controlled by pre-HSCT treatment. 5 HLH activity at the time of HSCT has also been associated with an increased likelihood of graft failure. 6 It has additionally been found that patients suffering from HLH have increased morbidity and complications when undergoing HSCT, including high rates of hepatic veno-occlusive disease. 7 HSCT while healthy, as in sibling B, could avoid post-transplant complications predisposed to by organ dysfunction from prior HLH effects or infections and organ injury related to prior therapies. Our treatment approach was unique in that it involved correction of FHL by preemptive allogeneic HSCT prior to disease manifestations. Our case descriptions additionally illustrate that a myeloablative preparative regimen, rather than the now preferred reduced intensity approach, should be considered in those undergoing preemptive transplantation given their lack of prior chemotherapy or immunosuppressive medication exposure. We believe that the measures taken in our case: prenatal genetic diagnosis, HLA typing during gestation, protective isolation and preemptive allogeneic HSCT prior to clinical manifestations of HLH, can be applied to other patients to increase survival in families where FHL is suspected.
